235 related articles for article (PubMed ID: 25596910)
1. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa.
Olivennes F; Trew G; Borini A; Broekmans F; Arriagada P; Warne DW; Howles CM
Reprod Biomed Online; 2015 Mar; 30(3):248-57. PubMed ID: 25596910
[TBL] [Abstract][Full Text] [Related]
2. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
3. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
4. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
5. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Ishihara O; Klein BM; Arce JC;
Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
[TBL] [Abstract][Full Text] [Related]
6. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.
Serour GI; Aboulghar M; Al Bahar A; Hugues JN; Esmat K
Reprod Biol Endocrinol; 2014 Jun; 12():52. PubMed ID: 24942155
[TBL] [Abstract][Full Text] [Related]
7. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Ishihara O; Arce JC;
Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
[TBL] [Abstract][Full Text] [Related]
8. High FSH dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers.
Munch EM; Sparks AE; Zimmerman MB; Van Voorhis BJ; Duran EH
Hum Reprod; 2017 Jul; 32(7):1402-1409. PubMed ID: 28472321
[TBL] [Abstract][Full Text] [Related]
9. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
[TBL] [Abstract][Full Text] [Related]
11. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome.
Yovich JL; Alsbjerg B; Conceicao JL; Hinchliffe PM; Keane KN
Drug Des Devel Ther; 2016; 10():2561-73. PubMed ID: 27563236
[TBL] [Abstract][Full Text] [Related]
12. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
13. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.
Olivennes F; Howles CM; Borini A; Germond M; Trew G; Wikland M; Zegers-Hochschild F; Saunders H; Alam V;
Reprod Biomed Online; 2009 Feb; 18(2):195-204. PubMed ID: 19192339
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
15. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin.
Bissonnette F; Minano Masip J; Kadoch IJ; Librach C; Sampalis J; Yuzpe A
Fertil Steril; 2021 Apr; 115(4):991-1000. PubMed ID: 33267959
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
18. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
Fernández-Sánchez M; Visnova H; Yuzpe A; Klein BM; Mannaerts B; Arce JC;
Reprod Biomed Online; 2019 Apr; 38(4):528-537. PubMed ID: 30713022
[TBL] [Abstract][Full Text] [Related]
19. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
[TBL] [Abstract][Full Text] [Related]
20. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.
Yacoub S; Cadesky K; Casper RF
J Ovarian Res; 2021 Feb; 14(1):31. PubMed ID: 33579321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
